Some clinicians use it off-label for older adults or perimenopausal patients struggling specifically with abdominal fat that has not responded to diet, exercise, or GLP-1 therapy alone
As the Times reported, Eli Lilly, which manufactures Mounjaro a similar medication that is approved for treating diabetes but also induces weight loss announced on Sept
A specialized loss function incorporating clinical benchmarks was implemented, with training conducted over 200 epochs
Good test-retest reliability was found for the ISI between Week 4 and 12 (ICC 0.819)
At Apex Skin, providers are seeing that firsthand
Despite the guideline-recommended use of both SGLT2i and GLP-1RA therapy, there is a paucity of real-world evidence on the long-term effects of combining SGLT2is with newer generation GLP-1RAs (including once-weekly GLP-1RAs, once-daily oral semaglutide, and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] agonists) on metabolic outcomes and other cardiorenal outcomes [22]